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Plasma N-glycans in colorectal 
cancer risk
Margaret Doherty1,2, Evropi Theodoratou3,4, Ian Walsh10, Barbara Adamczyk1,5, Henning 
Stöckmann1, Felix Agakov6, Maria Timofeeva  4, Irena Trbojević-Akmačić7, Frano Vučković7, 
Fergal Duffy1, Ciara A. McManus1, Susan M. Farrington4, Malcolm G. Dunlop4, Markus Perola8, 
Gordan Lauc7,9, Harry Campbell3,4 & Pauline M. Rudd1
Aberrant glycosylation has been associated with a number of diseases including cancer. Our aim was 
to elucidate changes in whole plasma N-glycosylation between colorectal cancer (CRC) cases and 
controls in one of the largest cohorts of its kind. A set of 633 CRC patients and 478 age and gender 
matched controls was analysed. Additionally, patients were stratified into four CRC stages. Moreover, 
N-glycan analysis was carried out in plasma of 40 patients collected prior to the initial diagnosis of CRC. 
Statistically significant differences were observed in the plasma N-glycome at all stages of CRC, this 
included a highly significant decrease in relation to the core fucosylated bi-antennary glycans F(6)A2G2 
and F(6)A2G2S(6)1 (P < 0.0009). Stage 1 showed a unique biomarker signature compared to stages 2, 
3 and 4. There were indications that at risk groups could be identified from the glycome (retrospective 
AUC = 0.77 and prospective AUC = 0.65). N-glycome biomarkers related to the pathogenic progress of 
the disease would be a considerable asset in a clinical setting and it could enable novel therapeutics to 
be developed to target the disease in patients at risk of progression.
Glycosylation is a highly prevalent and structurally diverse post translational modification which not only dic-
tates the biological activity of proteins but influences cellular proliferation, inflammatory processes and metasta-
sis1,2. Glycosylation is designated N-linked or O-linked depending if the glycosidic moiety occurs at Asn residues 
or at Ser/Thr residues, respectively3–5. Alterations due to physiological and pathophysiological conditions alter the 
‘normal’ glycosylation profile. For example, the expression and activity levels of glycosidases and glycosyltrans-
ferases have a large influence on the abundance and distribution of glycans6,7. In a given physiological state, glyco-
form populations are reproducible; therefore, disease-associated alterations may provide diagnostic biomarkers. 
Analysis of the glycosylation pattern in biofluids such as serum or plasma may therefore be expected to provide 
useful biomarkers as the host responds to disease or as tumours secrete certain proteins8,9,. Previous research on 
lung10,11, breast12–14, ovarian15,16, periampullary17 and stomach18 cancer confirm the significance of the abundance 
of specific serum or plasma N-glycan structures (e.g. increased levels of sialyl Lewis X (SLeX)) to be hallmarks of 
cancer progression.
Colorectal cancer (CRC) is the 4th most commonly diagnosed cancer in UK (13% of all cancers) and the 2nd 
most common cause of cancer death (10% of total) (Cancer Research UK). In previous research we have found 
that CRC risk is linked to specific glycosylation changes in Immunoglobulin G (IgG) glycosylation, including 
a decrease in IgG galactosylation and IgG sialylation and an increase in core-fucosylation of neutral glycans 
with concurrent decrease of core fucosylation of sialylated glycans19. Subsequently, we have also reported that 
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decreased galactosylation, decreased sialylation (of fucosylated IgG glycan structures) and increased bisecting 
GlcNAc in IgG glycan structures were strongly associated with all-cause and CRC mortality20.
In this study a high-throughput (HTP) automated ultra-performance liquid chromatography 
(UPLC)-fluorescent method was used to examine the plasma N-glycome from over one thousand patients diag-
nosed with CRC and significant cancer associated N-glycan alterations were identified in relation to CRC risk. 
Glycoproteins account for the majority of plasma proteins and the contribution of the highly abundant glyco-
proteins to the prevailing serum/plasma N-glycome have previously been documented21,22. It has been shown 
that many of these glycoproteins are implicated in diseases such as cancers, autoimmune disease and congenital 
disorders of glycosylation. Therefore by measuring the relative abundance of glycans released from these glyco-
proteins potential diagnostic biomarkers could be revealed and targeted treatments employed21. UPLC hydro-
philic interaction liquid chromatography with fluorescence detection (HILIC)23,24 was utilized to characterise the 
glycosylation profile of plasma samples from 633 CRC patients and 478 matched healthy population controls. The 
differences in relative abundance of glycans between cases and controls and the determination of correlations in 
the context of body mass index (BMI), C-reactive protein (CRP), family history, non-steroidal anti-inflammatory 
drug (NSAID) intake, physical activity and smoking habits were investigated. Importantly, we also included CRC 
stage results in our analysis. Finally, the predictive value of the relative glycan abundances to discriminate CRC 
from healthy control and identify at risk individuals using optimized classification algorithms was assessed.
Results
Total plasma N-glycan composition was determined by UPLC analysis of 2AB-labelled glycans as reported for 
HPLC25 and more recently for UPLC where Saldova et al.12 carried out extensive glycan analysis using exoglycosi-
dase sequencing and MS to confirm all structures and populate a database. The chromatogram was integrated into 
42 distinct individual peaks. The Oxford nomenclature has been used to annotate individual glycan structures26 
where A represents the number of antennae present, F indicates the fucose, B indicates the presence of a bisecting 
N-acetylglucosamine, G represents galactoses and S denotes sialic acids (Fig. 1). A representative chromatogram 
showing separation of the plasma glycome into predominant structures is shown in Fig. 2a and Supplementary 
Fig. 1. Each glycan identified, its peak number and GU value is shown in Supplementary Table 1.
Clinical features. The distribution and significant clinical features for the CRC patients and healthy controls 
is summarized in Table 1. Family history of CRC cancer was statistically significantly different between CRC cases 
and controls (P-value = 3.81E-39). Other categorical features such as smoking status, physical activity, gender and 
NSAIDs intake showed no statistical significance in this subset of the SOCCS study. However, NSAIDs intake was 
Figure 1. The Oxford notation by example. Inset: the most common residues in N-glycans and their linkages. 
Note that linkage information may be left ambiguous e.g. F(6)A1[3] may be written FA1.
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approaching significance (P = 6.62E-02) but did not pass Bonferroni correction. Plasma levels of CRP were found 
to be statistically significantly increased (P = 8.61E-11) in CRC. Interestingly, low BMI was associated with a low 
risk of CRC (P = 1.31E-0.7). Only the statistically significant variables of CRP, BMI and cancer family history 
were analysed further to explore their associations with the glycan traits.
Figure 2. (a) A representative chromatogram from human plasma N-glycome and peak assignments from 
the CRC cohort. Significant peaks (found on training set of 625 patients vs. 468 control) are coloured in red 
(increased in CRC) and blue (decreased in CRC). ‘*’ indicates one of the top five peak abundance changes (i.e. 
lowest p-value). (b) Significant peaks are marked decreased (blue) or increased (red) in all CRC and four stages 
of CRC.
Feature CRC (n = 625) Control (n = 468) P-value
Age
(median[IQR]) 52 (47–55) 53 (48–56) 2.32E-02
BMI
(median[IQR]) 26 (23–29) 28 (26–31) 1.31E-0.7
CRP
(median[IQR]) 0.36 (0.12–1.635) 0.18 (0.09–0.60) 8.61E-11
KCalories
(median[IQR]) 2527 (2006–3366) 2572 (2055–3238) 4.63E-01
Gender
(male/female) 54.24/45.76 55.34/44.66 7.59E-01
Family history
(Low/medium or high/
unknown)
67.84%/27.04%/5.12% 96.03%/1.05%/2.93% 3.81E-39
Physical activity
(very low or low/medium 
or high/unknown)
58.08%/14.08%/27.84% 62.18%/14.96%/22.86% 3.49E-01
Smoking status
(non/current or former/
unknown)
36.96%/37.44%/25.60% 38.25%/41.03%/20.73% 2.62E-01
NSAIDs
(no/yes/unknown) 60.00%/15.04%/24.96% 59.62%/19.66%/20.73% 6.62E-02
Table 1. Descriptive information for 625 CRC patients vs. 468 healthy controls. Underlined p-values show 
significant differences between CRC and control. To highlight biological variation for continuous variables 
the median and interquartile ranges (IQR) are shown. IQR shows the spread of the continuous variables. For 
categorical features the basic counts are shown.
www.nature.com/scientificreports/
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Significant peaks, glycans and glycan groups. Statistically significant differences were observed for 18 
out of the 42 glycan peaks in the chromatogram. Supplementary Table 2 shows the differential analysis of each 
peak with their P-values. Figure 2a summarizes the statistically significantly increased and decreased predom-
inant glycans, their retention times (RTs), GUs and relative abundance (i.e. peak areas) on the chromatogram. 
Except for the first peak, the significant glycans eluting at earlier retention times (pre major peak 23) were consist-
ently decreased in CRC, while the later eluting glycans were consistently increased (post major peak 23). Of the 
peaks decreased in CRC, the majority had core fucosylated structures and all were bi-antennary, contained mono 
or di-galactosylated moieties and at most one involving sialic acid. The most statistically significant decrease came 
from the F(6)A2G2 (GP11) glycan (P = 2.00E-16). Increased in CRC were glycans containing 2 or more sialic acid 
and galactose residues. In the tail end region of the chromatogram the majority CRC abundant glycans came from 
highly branched structures (>3 GlcNAc antennae), highly galactosylated (>3 galactose) and highly sialylated 
(>3 sialic acids) glycans. The most statistically significant increase (P = 2.00E-16) came from the tetra-antennary 
structure A4G4S[3,3,3,3]4 (GP39). All isomers of A4G4S4 were consistently increased in CRC.
Cancer stage and biomarkers. Figure 2b shows the significant biomarker signatures across the four stages 
of CRC. A decrease of peak 11 (F(6)A2G(4)2) and peak 18 (F(6)A2G(4)2 S(6)1) is a constant biomarker across 
all stages of CRC. However, stage 1 has an evidently different biomarker signature compared to stages 2, 3 and 4. 
That is, stage 1 has no significant increase in the tail region (peaks 36–42).
Grouping glycans by structural features. Many of the individual structures share the same structural 
features: (galactose (G), sialic acid (S) and core-fucose (F)), thus additional derived traits were calculated that 
average these features across multiple glycans (Supplementary Table 4). Significant differences were observed 
in several features of the derived glycome traits (Table 2, Fig. 3). The first peak, GP01, containing the only 
non-galactosylated glycan (G0) was increased in CRC (P = 1.41E-04 for G0; Table 2; Fig. 3). When there was 
galactosylation, only di-galactosylation was significantly decreased (P = 1.27E-11 for G2; Table 2; Fig. 3), while a 
concurrent increase in tri and tetra galactosylation was observed (P = 6.25E-10 for G3 and P = 2.87E-08 for G4; 
Table 2, Fig. 3). Neutral and low branching sialylation (S0 neutral, S1 and S2) were continuously decreased in 
CRC, but only S1 was significantly so (P = 4.94E-06 S1; Table 2 and Fig. 3). There was a significant switch to an 
increased abundance in CRC for tri and tetra sialylation (P = 2.37E-11 for S3; and P = 2.74E-06 for S4; Table 2 and 
Fig. 3) with end RTs. In particular, the last seven eluting peaks containing tri/tetra-sialylated glycans collectively 
showed significance (P = 9.94E-09 for Tail in Table 2; Fig. 3). Core fucosylation was decreased in CRC when the 
glycans were neutral, and more so when neutral with one or two galactose: i.e. P = 1.51E-03 for coreFneutral 
Table 2 and P = 3.57E-09 for coreFneutralG1G2 Table 2. Finally, grouping bisecting or outer fucosylated peaks 
showed insignificant change in abundance between CRC and control (Table 2; Fig. 3). The relationship between 
the specific glycan biomarkers and the derived biomarker traits are summarized in supplementary Table 5. All 
Glycan trait
CRC (n = 625) 
(median[IQR])
Control (n = 468) 
(median[IQR])
Δ peak 
area* p-values
G0 2.23 (1.59–3.02) 2.01 (1.44–2.78) 0.29 1.41E-04
G1 8.49 (7.14–9.63) 8.695 (7.5–9.8175) −0.22 1.99E-02
G2 65.34 (63.04–66.95) 66.6 (64.82–68.05) −1.79 1.27E-11
G3 13.97 (12.14–15.99) 13.295 (11.7225–14.98) 0.63 6.25E-10
G4 6.5 (5.26–8.05) 6.02 (5.03–7.0375) 0.81 2.87E-08
S0neutral 11.91 (9.79–13.73) 12.215 (10.2075–14) −0.18 1.13E-01
S1 23.72 (21.95–25.56) 24.29 (22.9125–25.825) −0.72 4.94E-06
S2 45.15 (43.41–46.83) 45.465 (43.785–47.14) −0.49 7.89E-01
S3 13.99 (12.36–15.92) 13.24 (12.005–14.5475) 0.93 2.37E-11
S4 1.96 (1.6–2.44) 1.72 (1.45–2.02) 0.34 2.74E-06
CoreFall 28.43 (25.16–31.28) 29.135 (26.535–32.105) −1.06 4.30E-03
CoreFneutral 18.07 (15.23–20.52) 18.78 (16.4025–21.095) −0.89 1.51E-03
CoreFneutralG1G2 6.05 (4.93–7.28) 6.685 (5.515–7.8675) −0.65 3.57E-09
OuterF 14.98 (13.27–16.58) 14.885 (13.47–16.46) 0.07 6.35E-01
Ball 5.06 (4.08–5.85) 5.115 (4.29–5.9575) −0.16 2.58E-01
Bneutral 4.03 (3.61–4.52) 3.95 (3.53–4.43) 0.15 3.46E-02
Tail 2.88 (2.43–3.51) 2.63 (2.26–2.98) 0.46 9.94E-09
Table 2. Plasma glycome composition in CRC patients and controls. Only the main derived traits describing 
glycome composition are shown. Directly measured glycan structures are available in Supplementary Table 1. 
Description of each derived trait is given in Supplementary Table 4. Bonferroni correction for multiple testing 
(P-values significance threshold <0.05/17 (0.003). *The difference between the mean peak areas (CRC – 
control). #Results reported on this column. G – galactose; F – fucose; B – bisecting GlcNAc, S – sialic acid. To 
highlight biological variation the median and interquartile ranges (IQR) are shown. IQR shows the spread of the 
relative abundances (i.e. summed peak areas).
www.nature.com/scientificreports/
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predominant potential N-glycan biomarkers in CRC plasma with potential glycoproteins involved are displayed 
in Table 3 and a comparison to the previous IgG analysis is outlined.
Glycan abundance changes related to CRP, BMI and family history. Higher abundance of the peak 
cluster (GP36, GP37, GP38, GP39, GP40, GP41 and GP42) containing mainly tri/tetra galactose/sialic acid gly-
cans was found to be highly correlated with CRP levels (see Pearson correlations in Supplementary Table 6). These 
peaks, which were found to be increased in CRC (see Fig. 2a, Table 2 and Supplementary Table 2) could therefore 
be considered markers for inflammation too. Conversely, core fucosylated peaks GP11 and GP18 were inversely 
correlated with CRP (Pearson 95% CIs: [−0.33, −0.25] and [−0.32, −0.24] Supplementary Table 6) thus higher 
abundance of FA2G2 and FA2G2S[6]1 glycans were indicators of normal body or little inflammation. BMI did not 
show any interesting correlations with glycan peak abundances. Interestingly, individuals with high or medium 
family history had significantly increased GP40 (P = 1.65E-03; Supplementary Table 6 and Supplementary Fig. 2).
Discriminating CRC cases from healthy controls. Discrimination models. We also optimized a simple 
machine learning algorithm to model the observed separation in the training data (625 CRC vs. 468 control). The 
optimized discrimination models were evaluated in a ten-fold cross validation. Clinical variables such as age, gen-
der, smoking status, BMI, CRP, physical activity and Kcalories were available in substantial numbers across both 
CRC cases and controls and therefore could be used in the optimization (see Table 1). However, cancer family his-
tory could not be used, as there were only 5 cases of high/medium family history in controls and they would not 
be representative for model optimization. Table 4 shows that using all glycan peak areas (without derived traits) 
as input, an Area Under the ROC Curve (AUC) of 0.765 was possible. Model performance of glycan and clinical 
features resulted in an improvement in AUC by 1% point (0.777 vs. 0.765; P = 9.48E-02; Table 4). We thought 
that CRP may be an interesting clinical feature to combine alone with all peaks, however using all peaks + CRP 
showed very little improvement over simply using all peaks alone (Table 4; AUC 0.763 vs. 0.765). Clinical features 
(age, gender, smoking status, BMI, CRP, physical activity and Kcalories) alone had only modest performance 
(AUC 0.613; P < 0.0001) suggesting the glycan information quantified in the peak areas is more discriminative 
at predicting colorectal cancer than any of the clinical features. CRP alone had almost random classification 
AUC (Table 4; AUC 0.569) suggesting it needed to be used in combination with other clinical features (Table 4; 
CRP AUC vs. Clinical only AUC; 0.569 vs. 0.613). Figure 4 shows the ROC curves for the best models in Table 4 
compared to clinical features and CRP only baselines. By design our models were tuned to produce a specificity of 
approximately 0.95 (5% false positive rate). This is because for cancer screening, where the target cancer has low 
occurrence in the screened population, the false positive rate needs to be very low27. At this 0.95 specificity the 
two models using all peaks alone and clinical features alone achieved a sensitivity of 0.3444 and 0.1343 respec-
tively (Table 4). This improved by 2% points to 0.3649 sensitivity (at ~0.95 specificity) when combining clinical 
and all glycan peak features (Table 4).
Furthermore, shown in Supplementary Table 7, all stages could be discriminated from healthy control with 
high AUC (stage 1: 0.777, stage 2: 0.781, stage 3: 0.781 and stage 4: 0.840). As one might expect stage 4 had the 
highest discrimination power (AUC 0.840, sensitivity 0.5287 and specificity 0.9477). More importantly, stage 1 
had a high discrimination power (AUC 0.777, sensitivity 0.3482 and specificity 0.9477) suggesting the glycome 
can also detect early stage CRC.
Figure 3. Boxplots showing increased and decreased glycan abundance for the derived glycome traits. The dots 
represent an individual’s relative abundance for the trait. Statistically significant traits can be found in Table 2.
www.nature.com/scientificreports/
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Predominant 
Glycan
Plasma 
CRC 
change
This 
work’s 
Peak
IgG change 
CRC19
IgG 
Peak 
from19
Likely plasma 
protein(s)* Amino acid
Protein plasma 
concentration (% of 
total)^
FA2 Increased GP01 Increased GP4 IgG Asn297, Asn322 (IgG3) 40.4%
FA2[6]G1 Decreased GP04 Decreased GP08 IgG Asn297, Asn322 (IgG3) 40.4%
FA2[3]G1 Decreased GP05 Decreased GP09 IgG Asn297, Asn322 (IgG3) 40.4%
A2[3]G1S[3]1 Decreased GP08 NF NF ? ? ?
A2G2 Decreased GP08 Decreased GP12 IgG, Apo Asn297 (IgG), Asn322 (IgG3)
40.4% (IgG), 0.5% 
(Apo)
FA2G2 Decreased GP11 Decreased GP14 IgG Asn297 (IgG), Asn322 (IgG3) 40.4%
FA2BG2 Decreased GP12 Decreased GP15 IgG Asn297 (IgG), Asn322 (IgG3) 40.4%
FA2G2S1 Decreased GP18 Decreased GP18 IgG, IgA, IgE, IgD, IgM, A2M
Asn297 (IgG), Asn322 
(IgG3), Asn340(IgA), 
Asn46(IgM), Asn209(IgM), 
Asn272(IgM)
40.4% (IgG), 9.0% 
(IgA), 0.1% (IgD), 
5.0% (IgM)
A2F1G2S1 Decreased GP20 NF NF Apo D, Haptoglobin
Asn98 (Apo D), 
Asn184(Hapto), Asn207 
(Hapto), Asn241 (Hapto)
0.3% (ApoD), 4.5% 
(Hapto)
A2BG2S2 Increased GP24 Decreased GP22 IgG Asn297 (IgG), Asn322 (IgG3) 40.4%
FA3G3S1 Increased GP24 NF NF ? ? ?
FA3BG3S1 Increased GP24 NF NF ? ? ?
A3G3S2 Increased GP27 NF NF B2, Apo D, Hapto, Sero
Asn65 (Apo D), Asn162 
(B2), Asn193 (B2), Asn184 
(Hapto), Asn211 (Hapto), 
Asn241 (Hapto), Asn432 
(Sero), Asn630 (Sero)
0.7% (B2),
0.3% (Apo D),
4.5% (Hapto),
8.5% (Sero)
A3BG3S2 Increased GP27 NF NF ? ? ?
FA3G3S3 Increased GP32 NF NF ? ? ?
A4G4S3 Increased GP37 NF NF AGP Asn72, Asn93, Asn103 2.6% (AGP)
A4F1G3S3 Increased GP38 NF NF AGP Asn93 2.6% (AGP)
A4G4S4 Increased GP42 NF NF AGP, Apo D, CP Asn65 (Apo D), Asn762 (CP)
2.6% (AGP), 1.2% 
(CP),
0.3% (ApoD)
A4F1G4S4 Increased GP42 NF NF AGP, CP Asn762 (CP) 2.6% (AGP), 1.2% (CP)
Table 3. Comparison between the IgG glycan markers19 to the plasma glycan markers found in this work. *The 
possible plasma protein and amino acid site involved for each glycan derived from21 and the previous IgG CRC 
study19, in bold the highest concentration. NF: not found in the IgG profile. For simplicity we did not separate 
by linkage isomers since all followed the same trend (e.g. A4G4S[3,3,3,3]4 and A4G4S[3,3,3,6]4 both increased 
in plasma CRC). Abbreviated proteins (UniProt ID)- AGP: Alpha-1-acid glycoprotein (P02763; P19652), 
A2M: Alpha-2-macroglobulin (P01023), Apo: Apolipoprotein B-100 (P04114), Apo D: Apolipoprotein D 
(P05090), CP: Ceruloplasmin (P00450), Hapto: Haptoglobin (P00738), B2: Beta-2-glycoprotein I (P02749). 
Sero: Serotransferrin (P02787). IgA: Immunoglobulin A (P01876, P01877), IgD: Immunoglobulin D (P01880), 
IgE: Immunoglobulin E (P01854), IgG: Immunoglobulin G (P01857, P01859, P01860, P01861), IgM: 
Immunoglobulin M (P01876, P01877), ?: unknown. ^Approx. derived from21.
Peaks + features AUC Sensitivity Specificity p-value
All peaks 0.765 0.318 0.949 9.8E-02
All peaks + clinical 0.770 0.373 0.949 *
All peaks + CRP 0.763 0.322 0.949 8.93E-02
Clinical only 0.613 0.150 0.949 <0.0001
Clinical only - CRP 0.529 0.075 0.949 <0.0001
CRP only 0.569 0.153 0.949 <0.0001
Table 4. 10-fold cross validation model performance to identify CRC. Discrimination models on the SOCCS 
dataset (625 CRC vs. 468 control). ‘All peaks’: 42 peak areas. ‘All peaks + clinical’: 42 peak areas, BMI, age, 
gender, smoking status, physical activity, NSAIDs intake, Kcalorie intake and CRP. ‘All peaks + CRP’: 42 peaks 
areas + CRP only. ‘Clinical only’: BMI, age, gender, smoking status, physical activity, NSAIDs intake, Kcalorie 
intake and CRP. ‘Clinical – CRP’ used all clinical features except family history and CRP. P-value column: ‘*’ 
best model, P-value AUC different from best model.
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Validating the discrimination model. All parameters of the discrimination model were optimized on the 
training set (625 CRC cases vs. 468 control). Then, the model was used to predict the probability of CRC on 18 
individuals in the validation set (8 CRC vs. 10 control). As we derived the cut-off threshold on the training set at 
95% specificity we expected highly accurate healthy control detection. Supplementary Table 8 shows that using 
peak area information alone none of the 10 healthy controls were classified as CRC while 4 of the CRC patients 
were flagged as cancer. In total, this test produced an accuracy of 77.8%, with a 100% and 50% specificity and sen-
sitivity respectively. Adding the clinical variables produced a sensitivity of 62.5% and a specificity of 90.0%. CRP 
alone degraded the sensitivity greatly suggesting again that richer information is present in the relative abundance 
of the N-glycans (i.e. peak areas).
At risk groups: As mentioned previously, high/medium family history contained higher levels of peak 40 
(predominantly glycan A4G4S[3,3,3,3]4) and therefore may represent a biomarker to identify at risk groups. In 
addition, the same glycan peak (A4G4S[3,3,3,3]4) was increased in individuals who were sampled before they 
developed colorectal cancer (FINRISK dataset; P = 1.10E-03; Supplementary Table 3). Further evidence that 
at-risk groups can be identified was confirmed by using all peak areas and age (allowed as both at risk and control 
groups were age matched) of individuals in our classification algorithm showing some discrimination power to 
identify at risk individuals (FINRISK dataset; Table 5; AUC 0.651).
Discussion
In this extensive comprehensive study, glycoforms were analysed in plasma from colorectal cancer patients and 
we assessed the correlation between specific glycan structures with associated CRC risk factors. Current CRC 
screening and surveillance strategies include colonoscopy, barium enema, sigmoidoscopy and faecal occult blood 
testing28. Using patient serum or plasma represents a much less invasive alternative and may improve patient 
compliance. Glycans in plasma are pooled from all cells in the body, and specific oligosaccharides produced 
during disease pathogenesis will be present and have already been directly correlated to various cancers11,29, and 
inflammatory conditions30,31. Bones et al. previously evaluated the contribution of glycosylation present on four 
highly abundant glycoproteins to the glycosylation profile of serum. The N-glycans displayed on IgG, transferrin, 
haptoglobin and α1-acid glycoprotein corresponded to the majority of peaks present in the serum N-glycome22. 
A recent review detailed the glycoforms present on 24 glycoproteins which account for the majority (30mg/mL- 
70–75mg/mL approximately) of the total plasma protein concentration21. Consequently, changes in the total 
plasma glycome are conceivably due to alterations in the glycosylation present in one or more of these highly 
abundant glycoproteins. In this study glycans were removed from their respective glycoproteins in the plasma 
samples by enzymatic digestion prior to separation by HILIC chromatography. Each glycoform was then quan-
tified in a relative manner. Thus, by comparing CRC patient samples against controls, we can identify glycan 
Figure 4. Classification of CRC patients using plasma glycans. ROC curve illustrating the performance of 
perceptron model in discrimination between CRC patients and healthy controls from SOCCS retrospective 
study (625 CRC vs. 468 control). “All peaks’: 42 peak areas. ‘All peaks + clinical’: 42 peak areas, BMI, age, gender, 
smoking status, physical activity, NSAIDs intake, Kcalorie intake and CRP. All peaks + CRP: 42 peak areas and 
CRP only. ‘Clinical only’: BMI, age, gender, smoking status, physical activity, NSAIDs intake, Kcalorie intake 
and CRP. ‘CRP only: the only variable used is CRP’.
Peaks + features AUC Sensitivity Specificity p-value
All peaks + age 0.651 0.125 0.950 *
All peaks 0.612 0.150 0.950 <0.0001
Table 5. 10-fold cross validation model performance to identify at risk groups. Discrimination models tested 
on the FINRISK dataset. ‘All peaks’: 39 peak areas and ‘All peaks + age’: all 39 peak areas and age of each person 
in the FINRISK dataset. P-value column: ‘*’ best model, P-value AUC different from best model.
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biomarkers and postulate from which of the 24 plasma glycoproteins they originated. By analysing and compar-
ing 625 CRC patients and 468 matching controls, we have found that CRC is associated with five major altera-
tions in plasma glycome composition: (i) agalactosylation - glycans with no galactose residues were increased 
in CRC (ii) galactosylation – there was a decrease in mono and di-galactosylated structures and an increase in 
tri and tetra-galactosylated glycans, (iii) sialylation - a decrease was observed in mono-sialyated glycans and an 
increase in tri and tetra-sialylated structures, (iv) GlcNAc antennae - a decrease in galactosylated and sialylated 
bi-antennary GlcNAc glycans and an increase in highly branched (≥3 GlcNAc antenna) glycans (v) core fucose - a 
decrease in neutral core fucosylated glycans in particular ones with one or two galactose residues. The glycans 
which increased in CRC (all –tri and tetra antennary, heavily sialylated and galactosylated structures) are mainly 
found on the plasma protein α−1-acid (AGP)21. AGP is an acute phase protein predominantly synthesized in 
hepatic parenchymal cells and is known to be augmented in inflammatory responses. The increase observed in 
this study correlates with a previous study which documented that AGP contributes bi-antennary di-sialylated, 
tri-antennary tri-sialylated and tetra-antennary tetra sialylated glycans to the serum N-glycome in stomach can-
cer22. A statistically significant positive correlation was found between AGP and SLex expression in CRC and it 
is thought that the glycoprotein may be a possible carrier of SLex32. Moreover, a positive correlation was demon-
strated between increased levels of these highly branched, sialylated and galactosylated glycans with circulating 
levels of CRP (discussed below). Conversely, the decreased glycans (core fucosylated, mono or bi galactosylation 
and mono-sialylation) appear to be derived from IgG and to a lesser extent IgM21.
Glycan Peak 1 was atypical since it was the only glycan with a low mass/retention time which displayed an 
increase in abundance in CRC. In particular, this peak contained predominantly a core-fucosylated agalacto-
sylated glycan (FA2). This concurs with previous studies which found increased levels of FA2 in ovarian can-
cer16,29, early stage breast cancer33 and stomach cancer18 with increasing disease pathogenesis. This was the 
only peak with a non-galactosylated component in our sample set and can be associated with IgG in plasma21. 
Furthermore, its abundance was also found to be increased in CRC in our previous IgG study19.
Specific glycans which were decreased in CRC were those containing either one sialic acid, one or two galac-
tose and/or a core fucose included: FA2[6]G1, FA2[3]G1, A2[3]G1S[3]1, A2G2, FA2G2, FA2BG2, FA2G2S[6]1. 
An increase in expression of FUT8 (responsible for the transfer of a core fucose residue to N-linked oligosaccha-
rides) in CRC has been described previously19. Additional support for FUT8 involvement is found in reports that 
mRNA MiR-198 represses tumour growth and metastasis in CRC by targeting FUT834. Highly branched glycans 
containing tri and tetra sialyated and galactosylated residues were found to increase in CRC and included isomers 
of: A4G4S4, A4F1G3S3 and A4G4S3 likely originating from the AGP glycoprotein21. Importantly, previous com-
prehensive analysis utilizing exoglycosidase sequencing12 enabled definition of isomeric biomarkers particularly 
important for specifying sialic acid linkages (e.g. A4G4S[3,3,6]3 as opposed to the more general A4G4S3 form).
A large group of consecutive peaks (36–42) with increased glycan abundance in CRC cases were termed the 
“Tail” peaks as they all occurred at the later retention times of the chromatogram. These glycan peaks consisted 
of tri and tetra sialyated and galactosylated glycans lacking a core fucose. GP38 and GP42 contained outer fucose. 
This increase in tri and tetra antennary structures containing tri-sialylated and tetra-sialylated glycans agree with 
previous findings observed in other cancers such as lung10, breast12, periampullary17, ovarian16, stomach18 and 
breast with higher circulating tumour cell count13. It was hypothesized that the reason for the increase was this 
region contained, in part, the SLex epitope10,13,16. In addition, our results and that of previous studies17 confirmed 
CRP or inflammation levels were positively correlated to this particular region of the glycosylation profile. These 
SLex containing glycoforms were shown to be elevated in acute phase proteins16. We can therefore hypothesize 
that the glycan abundances here mainly originate from the AGP acute phase glycoprotein21. Additional evidence 
for tri and tetra sialylated glycoforms points towards altered expression of the enzyme ST6Gal-I in various can-
cers thus increasing levels of tri and tetra α2–6 sialic acid glycans35,36.
Categorising glycans by specific properties allowed a concise description of the global features which are up 
and down regulated in CRC. When analysing the peaks in structural groups, bi-antennary bi-galactosylation (G2) 
was the strongest biomarker decreased in abundance in CRC cases followed by mono-sialyation and core fucosyl-
ation. A decrease in mono-sialylated (S1), α1–6 linked core fucosylated and bi-galactosylated (G2) glycans were 
all previously observed in lung10 and breast12 cancer. The increases in G3, G4, S3 and S4 were also consistent with 
previous lung10, periampullary17 and breast12 cancer N-glycan analysis.
Finally, CRP measurements (known to indicate the presence of inflammation) were positively correlated with 
tri and tetra sialylation and galactosylation (AGP glycans) and negatively correlated with FA2G2 and FA2G2S[6]1 
glycans (IgG glycans). This concurs with a previous study, where similar changes were found to occur after major 
surgery37. These glycan changes were also reported previously to be correlated with inflammation38, Ulcerative 
Colitis and Crohn’s Disease39.
The tetra-antennary structure A4G4S[3,3,3,3]4 was significantly increased in individuals with high/medium 
family history (P = 1.10E-03 Supplementary Table 6). This glycan is highly branched and requires activity of the 
GNT-V protein, which is a product of the MGAT5 gene. This gene has been implicated in ulcerative colitis40, 
gastric41 and small cell lung cancer42. To the best of our knowledge, this is the first report of a specific glycan level 
being associated with colorectal cancer family history. Thus, increased levels of A4G4S[3,3,3,3]4 is a marker for 
not only CRC but high/medium cancer family history too. The ability to identify at-risk individuals before the 
onset of colorectal cancer through statistical analysis adds further credibility to this investigation, individuals who 
were sampled at a healthy stage from Finland who later developed CRC also had significantly increased levels of 
A4G4S[3,3,3,3]4 perhaps indicating that it is a marker for ‘high potential to develop CRC’. Moreover, the at-risk 
group could be identified with discrimination significantly above random (FINRISK dataset; AUC 0.651). This 
may also indicate glycans can change in response to heritable mutations in certain genes and requires further 
investigation.
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The integrated plasma UPLC chromatograms contained a much more detailed and complex set of glycan 
types than our previous IgG study where di-sialylated antennary structures were the largest glycan structure 
observed19. As a consequence, the spectrum of glycan types in this plasma UPLC analysis is greater with tri and 
tetra sialylated and galactosylated structures assigned. The IgG analysis was based on a similar SOCCS sample 
set allowing us to compare both studies. Interestingly, when the same glycan was statistically significantly altered 
in CRC for the both IgG and plasma analysis, only one increase/decrease conflict occurred (Bisecting GlcNAc 
A2BG2S2 Table 3). This is possible as in IgG analysis the glycoprotein was initially isolated from the plasma sam-
ples prior to glycan analysis whereas here the source of glycan abundance comes from multiple glycoproteins. In 
both sources there was a consistent increase of agalactosylated FA2 and decreases for all structures with two ter-
minal galactoses (A2G2 (GP8), FA2G2 (GP11), FA2BG2 (GP12) and the mono sialic acid structure FA2G2S[6]1. 
All these glycans are predominately derived from IgG in plasma as summarized in21. The only difference between 
IgG and plasma was the opposite trends for core fucose derived traits (e.g. neutral core fucose peaks increased 
significantly in IgG but decreased significantly here, see coreFneutral in Table 2). This is not unexpected, since 
fucose on IgG has a very specific function and is presumably regulated in a different way in B cells and in liver43. 
In addition, IgG is over 90% core-fucosylated whereas in whole plasma, in addition to IgG, there are three other 
glycoproteins which dominate the glycan profile22 with the most abundant peak an afucosylated structure, namely 
A2G2S[3,6]2.
Discriminating healthy individuals from CRC individuals using simple classification algorithms and relative 
glycan abundance showed good performance. A logistic regression discrimination model was created in our 
previous work on IgG19 and a simple machine learning model was optimized for this work. Both had very similar 
model performances ~0.77 AUC suggesting a possible upper limit. Using glycan abundance information (peak 
area) improved discrimination substantially over the model using only clinical variables (AUC 0.777 vs. 0.613; 
Fig. 4) suggesting the glycan abundance patterns are much stronger at classifying CRC from healthy control (the 
same was concluded in the IgG study19). Given the good discriminative power of these models, glycan data in 
combination with other biomarkers/risk factors merit further evaluation in future studies, for example in assess-
ing models to achieve population stratification of risk to guide CRC screening. Perhaps, by using a combination of 
genomic information, to complement the glycomics evidence, such as single nucleotide polymorphism mutations 
we could increase the sensitivity and specificity of the model. For instance, a recently highly publicised blood test, 
CancerSEEK, measured levels of circulating proteins and mutations in cell-free DNA44. CancerSEEK could be 
combined with our orthogonal glycomics method to achieve even greater sensitivity and specificity.
By grouping the patients into stage 1, 2, 3 and 4 of the disease a decrease of F(6)A2G(4)2 and F(6)
A2G(4)2S(6)1 across all stages of CRC was observed. However, stage 1 had a unique biomarker signature com-
pared with later stages of the disease. In particular there was no significant increase in the tail region (peaks 
36–42) of Stage 1 CRC. Considering this region was correlated with CRP (inflammation) it may be possible that 
because stage 1 CRC has not yet metastasized inflammation may not be present yet. If this is true the tail region 
of (peaks 36–42) the chromatogram could be used to highlight a change from stage 1 to more serious, inflamed, 
stages (2, 3 and 4) but this needs further investigation. This would likely be due to increases in acute phase pro-
teins as the cancer progresses to more serious stages and with them increases in tri and tetra sialylation/galacto-
sylation (i.e. acute phase protein predominately contain these glycans21).
This is the first study of this magnitude to examine the complexities of the plasma N-glycome and correlate 
changes to CRC risk. The demographic included the majority of hospitals in Scotland and is therefore broadly 
representative of the Scottish CRC population. A newly developed high throughput automated robotic platform 
was utilized to isolate the glycans prior to UPLC-florescence. Overall, the significant changes observed in plasma 
correlated with changes shown in our recent IgG study adding further merit to this reproducible glycomic tech-
nology. Spurious differences between cases and controls were minimized by carrying out the glycan analysis 
blind to CRC status, plasma was stored at −80 °C until required, and all samples were treated in exactly the same 
manner.
A limitation of this study was that a single measurement of the glycosylation status from each patient was 
taken at a given time point. Although unlikely it might be possible that part of the differences we observe may be 
due to slight technical variation. Environmental factors such as age and obesity are known to influence protein 
glycosylation. We have taken this into account in our analyses and adjusted accordingly for these contributing 
factors, however, it remains possible that glycosylation changes observed are due to the occurrence of cancer 
(reverse causality). We endeavoured to investigate this further by analysing a prospective cohort and we observed 
that CRC cases could be identified with discrimination significantly above random. In addition, GP40 in the 
SOCCS study and GP41 in the prospective study both contained increased levels of the glycoform found to be 
associated with family history. However, the pattern for the remaining glycoforms was different between the 
two datasets. These differences could be explained by the fact that N-glycoforms were measured in the serum in 
the FINRISK cohort and in the plasma in SOCCS. However, the observed differences in SOCCS can also be a 
result of the tumour presence (rather than influencing the risk of developing CRC – reverse causality). Finally, 
the observed differences between CRC cases and controls in SOCCS might be due to the operation for tumour 
removal that CRC cases had undergone. A recent study examining alterations in the plasma N-glycome after 
cardiac surgery revealed a significant decrease in all sialylated glycans, excluding bi-antennary, di-sialylated struc-
tures and tetra-antennary fucosylated structures with the notable exception of SLeX which decreased initially 
but subsequently increased as the inflammatory response was stimulated45. Therefore, comparing our findings 
with those of the cardiac surgery patients, the decrease in mono-sialyated glycans that we observed in our CRC 
patients might be due to surgery. However, all other four major glycan alterations observed (including changes in 
agalactosylation, galactosylation, GlcNAc antennae and core fucosylation) were not observed in cardiac surgery 
patients and may be specific to CRC disease.
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In conclusion, this study has demonstrated significant differences in whole plasma glycome composition 
between colorectal cancer patients and controls. Although we were not able to detect the majority of these differ-
ences in historical samples (possibly due to reverse causality, inadequate study power or different type of sample) 
the observation that at-risk groups could be segregated from the population via statistical analysis in both sets 
of cohorts shows potential. N-glycome biomarkers in conjunction with other biomarkers/risk factors warrant 
further investigation in future studies, in assessing models to achieve patient stratification of associated risk and 
to facilitate CRC screening.
Methods
Studies. The Study of Colorectal Cancer in Scotland (SOCCS) (1999–2006) is a case control study designed 
to identify genetic and environmental factors associated with non-hereditary colorectal cancer risk and survival 
outcomes. Approval for the study was obtained from the MultiCentre Research Ethics Committee for Scotland 
and Local Research Ethics committee, and all participants gave written informed consent. All methods were 
performed in accordance with the relevant guidelines and regulations. The study has been described in detail 
elsewhere46. The present study includes a subset of 633 patients with pathologically confirmed colorectal adeno-
carcinoma and 478 age and gender matched controls. We randomly split the data into a training set used to find 
statistically significant biomarkers (625 patients, 468 controls) and a validation set used to discriminate CRC from 
control (8 patients, 10 control). CRC stage was also available for the training set (stage 1 = 110, stage 2 = 199, stage 
3 = 231 and stage 4 = 85) and validation set (stage 1 = 2, stage 2 = 2, stage 3 = 2, stage 4 = 2).
Blood was collected post-surgery and transferred to the research centre within 72 hours of sampling. Plasma 
was prepared by gentle centrifugation of sodium EDTA tubes and 1.5 ml of each participant’s plasma was stored 
at −80 °C. Each sample was barcoded to ensure analysis was carried out blind. Participants completed a detailed 
lifestyle questionnaire, a semi-quantitative food frequency (http://www.foodfrequency.org) and a dietary sup-
plements questionnaire. These questionnaires provided information on age, sex, BMI, cancer family history 
(low, medium or high), smoking (non-smokers, current), physical activity (very low, low, medium or high), 
non-steroidal anti-inflammatory drugs (NSAIDs) intake (yes, no) and total calorie intake. Plasma levels of 
C-reactive protein (CRP) were also measured. Plasma glycome composition was analysed in samples collected 
after CRC diagnosis (for CRC cases) or recruitment (for population controls). To investigate glycan abundance 
changes against clinical variables such as CRP and family history, a larger unmatched sample set was also used 
from the SOCCs study, containing 1435 patients and 553 controls.
FINRISK. A second serum sample set to investigate risk factors in the Finland population47 was used. 
Population data were searched for patients with incident CRC during 10 years follow-up. Individuals were sam-
pled before developing CRC. 40 individuals (mean age 60 (interquartile range 52.8–68.71)), who developed CRC 
and no other chronic disease, were identified and included in the study. 80 age and sex matched controls (median 
age 60.32 (interquartile 54.7–68.8)), who remained healthy during follow-up period, were selected from the same 
population and serum N-glycans were analysed.
Experimental protocol. A detailed structural analysis and quantification of oligosaccharides in human 
plasma was performed using a HTP platform for N-glycan analysis - UPLC hydrophillic interaction liquid chro-
matography (HILIC) with fluorescence detection - a technique that separates structures on the basis of their 
hydrophilicity23,24. This well-established protocol was further developed, optimised and automated on a robotic 
platform48. Several bioinformatics tools were developed to assist the analyses, including modelling algorithms, 
statistical methods and database matching in GlycoBase49, a library containing H/UPLC HILIC data for many 
2AB labelled N-linked and O-linked glycans (https://glycobase.nibrt.ie/).
Briefly, the glycoproteins in the plasma samples were denatured and the attached glycans released by PNGase 
F. A further hydrazide-mediated clean-up step was carried out subsequent to 2AB labelling as described else-
where50. Finally, glycans were immobilized on solid supports and contaminants removed. Alternatively, for the 
FINRISK replication cohort serum glycans were 2AB labelled immediately after protein deglycosylation and 
cleaned-up using hydrophilic GHP filter with cold 96% acetonitrile before the UPLC analysis, as previously 
described51. Separation of 2-AB-derivatized N-glycans was carried out by UPLC with fluorescence detection on 
a Waters Acquity UPLC H-Class instrument consisting of a binary or quaternary solvent manager, sample man-
ager, and fluorescence detector under the control of Empower 3 chromatography workstation software (Waters, 
Milford, MA, USA). A fifth-order polynomial distribution curve was fitted to the dextran ladder to assign glu-
cose unit (GU) values from retention times (using Empower software) as described previously25. The GU val-
ues obtained for each glycan are reproducible and predictive, and therefore initial structural assignments were 
possible using recorded GU values in GlycoBase49. A detailed protocol is given in the supplementary material 
including reagents used with their concentrations and incubation times. In addition, the slightly different UPLC 
conditions for the FINRISK sample set are summarized in the supplementary material.
Nomenclature for glycan molecules. The nomenclatures used to describe the structures are Oxford 
nomenclature, with shorthand descriptors as previously described26. The N-linked glycan core structure is com-
posed of a trimannosylchitobiose core and thus is generally abbreviated M3. Antennae on N-glycans are abbre-
viated A1, A2, A3 or A4 composed of an M3 core with one, two, three and four arm GlcNAc extensions. Further 
extensions include galactose additions to each antennae (e.g. bi antennae and galactose - A2G2); addition of sialic 
acids to galactose (e.g. A2G2S2). If fucose is linked to the reducing end GlcNAc of the chitobiose core, generally 
an F is used prior to the shorthand descriptor to indicate the presence of the core fucose (e.g. FM3, indicating a 
core fucose attached to the GlcNAc of the chitobiose core of the core N-linked structure). Another substitution 
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that can occur is the addition of a GlcNAc to the middle mannose of the chitobiose core, resulting in a bisecting 
GlcNAc. A structure with this modification is referred to as a bisected glycan, for example a bisected A2G2 can be 
represented by A2BG2. A comprehensive list of examples is provided in Fig. 1.
Computational procedures. Statistical analysis. Clinical characteristics among patients and controls 
were compared using a Tukey honest significant difference (HSD) test with ANOVA for all continuous varia-
bles. Peak areas are compositional data (presented as a % of the total area under the graph) and therefore the 
constant-sum constraint (CSC) occurs. The CSC means individual variables do not vary independently, violating 
common assumptions upon which standard statistical analyses are performed. This was avoided by performing 
a log transform, log(Peaki)/(100-Peaki), on all peak areas52. To calculate the P-values we controlled for covariates 
by creating a linear regression model with available covariates: age, family history and gender for the SOCCS set 
and age for the FINRISK set. For categorical variables Fisher exact tests were performed. Correction for multiple 
testing was performed using a simple Bonferroni correction with ANCOVA and Fisher test results considered 
statistically significant when P-values were < 0.05/(number of tests).
Peak and clinical feature associations. Peak relative abundances were correlated with continuous variables using 
Pearson correlation (R) and significance calculated using the t-test (null hypothesis that there is no correlation). 
Categorical clinical features (e.g. family history) were associated with peaks using Tukey HSD and ANOVA using 
linear models with age and gender covariates.
Classification model. Simple perceptron53, models with sigmoidal activation functions were optimized on the peak 
areas. In order to test the performance of the models the training set was split and a 10-fold cross validation (90% of 
data for finding model parameters and 10% of data to test the model repeated 10 times) performed. To confirm the 
accuracy of the model, a perceptron model was optimized on the training set and the optimized model was used to 
classify CRC on the validation set. Predicting the presence or absence of CRC is a binary classification problem with 
discriminative power indicated by area under the Receiver Operating Characteristic curve (referred to as AUC)54. 
Prediction models were deemed statistically different by bootstrapping the AUC using the pROC package55.
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